Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

Coronavirus Dashboard (COVID-19) - Update Log

May 18, 2020 Updates
American Medical AssociationCOVID-19 Update for May 18, 2020Play Video
NewsSARS antibodies can block COVID-19 infection: study
PARIS, FRANCE -- An antibody from a patient who recovered from SARS has been shown to block COVID-19 infection in a laboratory setting, researchers said Monday in another potential breakthrough in the search for coronavirus treatment.
Website
NewsPhase IIb trial to study hydroxychloroquine and azithromycin as COVID-19 treatment launched
A double-blind clinical trial has begun in the US to study hydroxychloroquine and azithromycin treatment in patients with COVID-19.
Website
NewsLipid mediators suggested as potential COVID-19 inflammation treatmen
A new article has outlined the body’s inflammatory response to COVID-19 infection, saying that lipid mediators derived from omega-3 fatty acids could prevent life-threatening inflammation.
Website
NewsHalifax - Canada vaccinology centre to conduct Canada's first COVID-19 vaccine trials
The Canadian Centre for Vaccinology will work with the Chinese pharmaceutical company CanSino Biologics and Canada’s National Research Council. The vaccinology centre operates as a collaboration between Dalhousie University, the IWK Health Centre and the Nova Scotia Health Authority.
Website
NewsCOVID-19 treatment: St. Elizabeth offers drug's first trial to its patients
St. Elizabeth Healthcare is the first U.S. location to offer a clinical trial of an inhaled drug that scientists hope can limit COVID-19 in patients with early stages of the lung illness.
Website
NewsCoronavirus Vaccine From Moderna Shows Early Signs of Viral Immune Response
An experimental vaccine from the U.S. biotechnology company Moderna Inc. showed signs that it can create an immune-system response to fend off the new coronavirus, offering tentative hopes in the global effort to combat the pandemic.
Website
May 17, 2020 Updates
NewsIf Oxford's coronavirus vaccine works, officials say UK will get it first
The U.K. government made a deal to get 30 million doses by September.
Website
NewsCoronavirus Vaccine Front-Runners Emerge, Rollouts Weighed
Governments and drugmakers are weighing how to roll out coronavirus vaccines, including reserving the first batches for health-care workers, as several shots race to early leads.
Website
May 15, 2020 Updates
American Medical AssociationCOVID-19 Update for May 15, 2020Play Video
NewsU.S. narrows down candidates in major push for COVID-19 vaccine
President Donald Trump said on Friday the U.S. government would invest in all the top coronavirus vaccine candidates and said a list had been narrowed to 14 promising possibilities with a plan to narrow further.
Website
NewsCoronavirus vaccine: Macaque monkey trial offers hope
A vaccine against coronavirus appears to have provided protection against the disease Covid-19 in six rhesus macaque monkeys.
Website
RegistriesThe International Database on Organ donation and Transplantation – COVID19

SARS-CoV-2 infection has been a challenge for health systems worldwide, causing a dramatic consumption of resources to cope with this pandemic caused by this recently identified virus. Solid information about SARS-CoV-2 (from a pathophysiological, clinical and therapeutic point of view) is scarce. On many occasions, these questions have been answered based on available knowledge from similar viruses such as SARS-CoV and MERS.

Due to the potential severity of this disease and the absence of current tools able to definitively modify its natural history, many are the ongoing research works that have been started since the description of the first case of COVID-19. Currently, our clinical practice in this type of infection is based on data especially from retrospective studies whose scientific power is questionable and which, on many occasions, provide contradictory messages.

These handicaps associated with the management and knowledge of COVID-19 extend, even with a greater lack of knowledge, to the population of recipients of a solid organ transplant (SOT) and to organ donation protocols, which have been adapted (in occasions drastically) to this new scenario. However, again, the data that supports these protocols and the available evidence on the management of organ donation and the recipient of a SOT are, likewise, of little scientific solidity.

As a result of this absence of solid evidence that allows for a significant improvement in the management of this risk population, The International Database on Organ donation and Transplantation – COVID19 (IDOTCOVID) has been designed. The present database tries to exhaustively collect the demographic, clinical, analytical and therapeutic data that of SOT recipients with COVID-19 and, afterwards, to extrapolate large-scale conclusions to provide reliable information and, more importantly, to guide in a solid way the future management of this population.

One of the main objectives of this project is the development of a tool that helps in the management of immunosuppression and the treatment of COVID19 infection in SOT recipients.

To achieve this, the following objectives have been designed to be developed in stages and progressively:

  1. Creation of an international database that includes all SOT recipient patients with COVID19 infection (confirmed or suspected);
  2. Inclusion of different clinical and analytical data with recognized prognostic factor in the general population;
  3. Inclusion of treatment data, including management of immunosuppression and clinical outcomes;
  4. Development of a Machine Learning algorithm that can assist the scientific community in updating their treatment management and immunosuppression protocols in this high-risk population;
Website
World Health OragnizationMedia briefing on COVID-19 Play Video
May 14, 2020 Updates
American Medical AssociationCOVID-19 Update for May 14, 2020Play Video
NewsA Coronavirus Vaccine Candidate In Six Days?
This Company Is Fast-Tracking Vaccine Development With The First Fully Automated Gene Synthesis Platform
Website
News3 challenges in creating a coronavirus vaccine – and how they are being overcome
Scientists across the globe are working on developing a vaccine to halt the coronavirus outbreak.
Website
PublicationAmerican Journal of Transplantation

Highlighted Articles:

May 5 - PERSONAL VIEWPOINT - Utilization of deceased donors during a pandemic: An argument against using SARS‐CoV‐2 positive donors
View Article

May 12 - PERSONAL VIEWPOINT - Use of SARS‐CoV‐2 infected deceased organ donors: Should we always “just say no?”
View Article

United StatesAmerican Society of Transplantation (AST)
The AST's Infectious Disease Community of Practice has received queries from transplant and donation colleagues regarding the novel coronavirus (2019-nCoV). The following FAQs were developed with input of members from both the organ donation and transplantation communities to relay information on the current state of knowledge.
PDF
May 13, 2020 Updates
American Medical AssociationCOVID-19 Update for May 13, 2020Play Video
TTS«HOT OFF THE PRESS» RECENT PUBLICATIONS IDENTIFIED BY TTS EDUCATION COMMITTEE ON COVID-19

This week's selection made by: Enver Akalin, Marlies Reinders, Pablo Uva, Nithya Krishnan, Manisha Sahay, Shannon Grappe and Annmarie Liapakis

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology.

Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S; COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group.
J Am Soc Nephrol. 2020 May 4.

This article emphasizes that AKI can be a severe complication of COVID-19 and the importance of assessing, defining, and reporting the course of AKI is highlighted.


Immediate impact of COVID-19 on transplant activity in the Netherlands.

de Vries APJ, Alwayn IPJ, Hoek RAS, van den Berg AP, Ultee FCW, Vogelaar SM, Haase-Kromwijk BJJM, Heemskerk MBA, Hemke AC, Nijboer WN, Schaefer BS, Kuiper MA, de Jonge J, van der Kaaij NP, Reinders MEJ.
Transpl Immunol. 2020 May 1:101304.

This article describes the enormous impact of COVID-19 on transplant activity in the Netherlands. There was a significant decrease in organ donation numbers affecting all organ transplant services and detrimental effect on transplantation numbers in children with end-organ failure. The paper also describes ongoing efforts focus on mitigation of not only primary but also secondary harm of the pandemic and to find right definitions and momentum to restore the transplant programs.


Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.

Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, Venkataramanan R, Lemaitre F.
Ther Drug Monit. 2020 Apr 15.

This article inform the clinicians about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.


Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.

Shah MB, Lynch RJ, El-Haddad H, Doby B, Brockmeier D, Goldberg DS.
Am J Transplant. 2020 May 5

This article presents a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The authors concluded that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies.


Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson D, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW.
N Engl J Med. 2020 May 7. 

This observational study involving 1446 patients with Covid-19 who had been admitted to the hospital documented that hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. 

World Health OragnizationMedia briefing on COVID-19 Play Video
May 12, 2020 Updates
American Medical AssociationCOVID-19 Update for May 12, 2020Play Video
NewsInterferon emerges as potential treatment for COVID-19
In the race to find an effective therapy for COVID-19, a class of drugs called interferons may be stepping into the spotlight thanks to encouraging results from two clinical trials and a call from a key Canadian expert to test the treatment on a larger scale.
Website
RegistriesSPLIT-TTS/NASPGHAN Pediatric Hepatology and Pediatric Liver/Intestinal Transplantation COVID registry  

The Society of Pediatric Liver Transplantation (SPLIT), a section of TTS, and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) have partnered to create a secure and de-identified online pediatric registry (for patients under the age of 21 years). Our intention is to collect and disseminate the experience of our community to better understand the clinical presentation, natural history and long-term outcomes in our hepatology and liver and intestinal transplant population. We are requesting all clinicians worldwide to report all cases of COVID -19 in children with chronic liver diseases (still with native liver), listed for pediatric liver/intestine transplantation, or have undergone liver and/or intestinal transplantation.  

We encourage you to complete this form even if the patient is in the middle of their COVID-19 course. This allows for timely dissemination back to our community. A weekly summary of COVID cases will be reported on the SPLIT COVID listserv, the NASPGHAN GI listserv and the NASPGHAN COVID website.   

To submit a case, please use this link or copy and paste the following url: https://is.gd/naspghansplitliversurvey  

Thank you to everyone in our community that is coming together at this time and for your efforts to serve our hepatology and transplant patients and support each other. Sincerely,

  • Mohit Kehar, Pediatric Gastroenterologist and Hepatologist, Queens University
  • Mercedes Martinez, Chair of the NASPGHAN Hepatology Committee and Medical Director of Intestinal Transplantation, Columbia University
  • Noelle Ebel, Transplant Hepatologist, Stanford University
  • Steven Lobritto, Chair of the SPLIT Quality Improvement and Clinical Care Committee, Medical Director of Pediatric Liver Transplantation, Columbia University
  • Vicky Ng, SPLIT President and Medical Director of Pediatric Liver Transplantation, University of Toronto  

This study has been granted REB/IRB clearance according to the recommended principles of Queen's University and Columbia University.

Website
May 11, 2020 Updates
American Medical AssociationCOVID-19 Update for May 11, 2020Play Video
WebinarMay 11 @3:00 PM EDT - COVID-19: Organ Donation and Transplant Town Hall Website
World Health OragnizationMedia briefing on COVID-19 Play Video
May 8, 2020 Updates
American Medical AssociationCOVID-19 Update for May 8, 2020Play Video
World Health OragnizationMedia briefing on COVID-19 Play Video
May 7, 2020 Updates
American Medical AssociationCOVID-19 Update for May 7, 2020Play Video
CanadaVaccines and treatments for COVID-19: List of all COVID 19 clinical trials authorized by Health Canada
Currently, the treatment of COVID-19 includes supportive care and treatment of any secondary infections, such as pneumonia. There are no drugs or vaccines approved, but there are now 20 clinical trials authorized in Canada with diagnostic equipment, supportive care and/or treatments for COVID-19.
Website
NewsWorld-first COVID-19 dialysis treatment comes from Canadian research team, doctors say
A team of researchers based in London, Ont. is the first in the world to attempt treating critical COVID-19 patients with a modified form of dialysis, doctors say.
Website
NewsWhat it's like inside the Oxford trial leading the race for coronavirus vaccine
As soon as the news of the novel coronavirus, which originated in Wuhan, China, broke in early January, scientists at the historic University of Oxford began to work on a vaccine. Just three months later, the university announced promising results in monkeys and its vaccine, called ChAdOx1 nCoV019, was entering into the clinical trial phase.
Website
NewsThe FDA Has Approved a Coronavirus Vaccine for Phase Two Trial
The Food and Drug Administration has given Moderna the green light to enter into phase two of trials with its vaccine against the novel coronavirus that causes COVID-19, in what the Boston biotech firm called a “crucial step forward.”
Website
NewsStudy Finds Nearly Everyone Who Recovers From COVID-19 Makes Coronavirus Antibodies
A recent study in Nature Medicine brings much-needed clarity, along with renewed enthusiasm, to efforts to develop and implement widescale antibody testing for SARS-CoV-2 [1]. Antibodies are blood proteins produced by the immune system to fight foreign invaders like viruses, and may help to ward off future attacks by those same invaders.
Website
NewsMystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19
The serious inflammatory syndrome sending some children and teens to the hospital remains extremely uncommon, doctors say. But if your child spikes a high, persistent fever, and has severe abdominal pain with vomiting that doesn't make them feel better, call your doctor as a precaution.
Website
NewsLead scientist reveals when vaccine may be ready
As Pfizer's coronavirus vaccine moves into human trials, Dr. Mark Mulligan discusses when we'll know
Website
NewsJapan approves Gilead’s remdesivir as a treatment for COVID-19
Japan on Thursday approved Gilead Sciences Inc’s remdesivir as a treatment for COVID-19, making it the country’s first officially authorized drug to tackle the coronavirus disease.
Website
NewsIs the world ready to produce a billion doses of a COVID-19 vaccine?
Imperial researchers say integrated modelling and flexible planning will be essential for manufacturers to meet the global COVID-19 vaccine demand.
Website
May 6, 2020 Updates
American Medical AssociationCOVID-19 Update for May 6, 2020Play Video
NewsThese 23 companies are working on coronavirus treatments or vaccines — here’s where things stand
The list includes Gilead Sciences and Moderna along with smaller biotechs
Website
NewsPfizer starts U.S. trials of experimental coronavirus vaccine
Pfizer Inc. has administered the first U.S. patients with its experimental vaccines to fight the disease caused by the novel coronavirus, part of a bid to shave years off of the typical time it takes to develop a new inoculation.
Website
NewsFrom Loss Of Smell To 'COVID Toes': What Experts Are Learning About Symptoms
When the coronavirus pandemic first emerged, public health officials told the world to watch out for its telltale symptoms: fever, dry cough and shortness of breath. But as the virus has spread across the globe, researchers have developed a more nuanced picture of how symptoms of infection can manifest themselves, especially in milder cases.
Website
TTS«HOT OFF THE PRESS» RECENT PUBLICATIONS IDENTIFIED BY TTS EDUCATION COMMITTEE ON COVID-19

This week's selection made by: Enver Akalin, Marcelo Cantarovich and Medhat Askar

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology.

Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S; COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group.
J Am Soc Nephrol. 2020 May 4.

This article emphasizes that AKI can be a severe complication of COVID-19 and the importance of assessing, defining, and reporting the course of AKI is highlighted.


Immediate impact of COVID-19 on transplant activity in the Netherlands.

de Vries APJ, Alwayn IPJ, Hoek RAS, van den Berg AP, Ultee FCW, Vogelaar SM, Haase-Kromwijk BJJM, Heemskerk MBA, Hemke AC, Nijboer WN, Schaefer BS, Kuiper MA, de Jonge J, van der Kaaij NP, Reinders MEJ.
Transpl Immunol. 2020 May 1:101304.

This article describes the enormous impact of COVID-19 on transplant activity in the Netherlands. There was a significant decrease in organ donation numbers affecting all organ transplant services and detrimental effect on transplantation numbers in children with end-organ failure. The paper also describes ongoing efforts focus on mitigation of not only primary but also secondary harm of the pandemic and to find right definitions and momentum to restore the transplant programs.


Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.

Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, Venkataramanan R, Lemaitre F.
Ther Drug Monit. 2020 Apr 15.

This article inform the clinicians about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.


Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.

Shah MB, Lynch RJ, El-Haddad H, Doby B, Brockmeier D, Goldberg DS.
Am J Transplant. 2020 May 5

This article presents a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The authors concluded that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies.


Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson D, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW.
N Engl J Med. 2020 May 7. 

This observational study involving 1446 patients with Covid-19 who had been admitted to the hospital documented that hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. 

World Health OragnizationMedia briefing on COVID-19 Play Video
May 4, 2020 Updates
April 29, 2020 Updates

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada